tiprankstipranks
Advertisement
Advertisement

HK:1952 Stock Latest News

Everest Medicines Grants New Options and Share Awards Under 2026 Scheme
Company AnnouncementsEverest Medicines Grants New Options and Share Awards Under 2026 Scheme
17d ago
1952
Everest Medicines Closes High-Value BTK Inhibitor Deal With Travere
PremiumCompany Announcements
Everest Medicines Closes High-Value BTK Inhibitor Deal With Travere
27d ago
1952
Everest Medicines Wins Shareholder Backing for All AGM Resolutions
PremiumCompany Announcements
Everest Medicines Wins Shareholder Backing for All AGM Resolutions
1M ago
1952
Everest Medicines to Commercialize Hainan Herui’s Budesonide Capsules in Mainland China
PremiumCompany Announcements
Everest Medicines to Commercialize Hainan Herui’s Budesonide Capsules in Mainland China
1M ago
1952
Everest Medicines’ Major Shareholder Boosts Stake, Signaling Confidence in Long-Term Outlook
PremiumCompany Announcements
Everest Medicines’ Major Shareholder Boosts Stake, Signaling Confidence in Long-Term Outlook
2M ago
1952
Everest Medicines Shareholders Approve Key Share Purchase Agreement
PremiumCompany AnnouncementsEverest Medicines Shareholders Approve Key Share Purchase Agreement
2M ago
1952
Everest Medicines Takes Exclusive Asia Rights to Dimerix Kidney Drug DMX-200
Premium
Company Announcements
Everest Medicines Takes Exclusive Asia Rights to Dimerix Kidney Drug DMX-200
2M ago
1952
Everest Medicines Substantial Shareholder CBC Group Raises Stake
Premium
Company Announcements
Everest Medicines Substantial Shareholder CBC Group Raises Stake
2M ago
1952
Everest Medicines Secures Greater China Rights to Presbyopia Eye Drop LNZ100
PremiumCompany Announcements
Everest Medicines Secures Greater China Rights to Presbyopia Eye Drop LNZ100
2M ago
1952
Everest Medicines Gains Vote of Confidence as Major Shareholder Boosts Stake
PremiumCompany Announcements
Everest Medicines Gains Vote of Confidence as Major Shareholder Boosts Stake
2M ago
1952
Everest Medicines Sets 2026 Virtual AGM, Seeks Fresh Share Repurchase and Issuance Mandates
PremiumCompany Announcements
Everest Medicines Sets 2026 Virtual AGM, Seeks Fresh Share Repurchase and Issuance Mandates
2M ago
1952
Everest Medicines Calls Virtual EGM to Approve Share Purchase Deal
PremiumCompany Announcements
Everest Medicines Calls Virtual EGM to Approve Share Purchase Deal
2M ago
1952
Everest Medicines Out-Licenses Kidney Drug Civorebrutinib to Travere in Deal Worth Up to US$1.14 Billion
PremiumCompany AnnouncementsEverest Medicines Out-Licenses Kidney Drug Civorebrutinib to Travere in Deal Worth Up to US$1.14 Billion
2M ago
1952
Everest Medicines Sets EGM Timetable and Delays Acquisition Circular
Premium
Company Announcements
Everest Medicines Sets EGM Timetable and Delays Acquisition Circular
2M ago
1952
Everest Medicines’ Major Shareholder Lifts Stake in Confidence Boost
Premium
Company Announcements
Everest Medicines’ Major Shareholder Lifts Stake in Confidence Boost
2M ago
1952
Everest Medicines Director and Major Shareholder Raises Stake in Company
PremiumCompany Announcements
Everest Medicines Director and Major Shareholder Raises Stake in Company
3M ago
1952
Everest Medicines Details PSVT Asset Purchase and Readies for China Launch
PremiumCompany Announcements
Everest Medicines Details PSVT Asset Purchase and Readies for China Launch
3M ago
1952
Everest Medicines to Buy Asia-Pacific Chronic Disease Portfolio in US$250 Million Deal
PremiumCompany Announcements
Everest Medicines to Buy Asia-Pacific Chronic Disease Portfolio in US$250 Million Deal
4M ago
1952
Everest Medicines Honorary Chairman Boosts Stake in Company
PremiumCompany Announcements
Everest Medicines Honorary Chairman Boosts Stake in Company
4M ago
1952
Everest Medicines Publishes Audited 2025 Annual Results and Report
PremiumCompany AnnouncementsEverest Medicines Publishes Audited 2025 Annual Results and Report
4M ago
1952
Everest Medicines to Acquire Cardiovascular Drug Assets in Up to US$50 Million Deal
Premium
Company Announcements
Everest Medicines to Acquire Cardiovascular Drug Assets in Up to US$50 Million Deal
4M ago
1952
Everest Medicines Pays RMB200 Million Deposit for Potential Asia-Pacific Chronic Disease Portfolio Acquisition
Premium
Company Announcements
Everest Medicines Pays RMB200 Million Deposit for Potential Asia-Pacific Chronic Disease Portfolio Acquisition
5M ago
1952

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >